Cilastatin

A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, IMIPENEM, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4.

Also Known As:

Networked: 106 relevant articles (18 outcomes, 17 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Tejedor, Alberto: 3 articles (01/2015 - 08/2010)
2.	Humanes, Blanca: 3 articles (01/2015 - 08/2010)
3.	Camano, Sonia: 2 articles (09/2012 - 08/2010)
4.	Lazaro, Alberto: 2 articles (09/2012 - 08/2010)
5.	Lazaro, Jose A: 2 articles (09/2012 - 08/2010)
6.	Campbell, Helen E: 2 articles (03/2006 - 05/2005)
7.	Edwards, Steven J: 2 articles (03/2006 - 05/2005)
8.	Álvarez-Sala, Luís Antonio: 1 article (01/2015)
9.	Lázaro, Alberto: 1 article (01/2015)
10.	Jado, Juan Carlos: 1 article (01/2015)

Related Diseases

1.	Infection 01/01/2014 - "aeruginosa), and lung (Klebisella pneumoniae) infection models, adding the dihydropeptidase I (DHP-I) inhibitor cilastatin in different proportions to the carbapenem. " 10/01/1997 - "The potent in vivo activity of BO-3482-cilastatin against such MRSA infections can be ascribed to the good in vitro anti-MRSA activity and improved pharmacokinetics in mice when BO-3482 is combined with cilastatin and to the bactericidal nature of the carbapenem." 05/01/1986 - "Based on the above results, MK-0787/MK-0791 appears to be effective against gynecological and obstetrical infections." 07/01/1986 - "Based on the above results, it can be concluded that MK-0787/MK-0791 is a safe and effective drug to use for the treatment of pediatric infections." 05/01/1986 - "These results suggest that MK-0787/MK-0791 will be useful for the treatment of obstetric and gynecologic infections."
2.	Pyelonephritis 02/01/1984 - "The therapeutic efficacy of N-formimidoyl thienamycin alone or coadministered with MK0791, an inhibitor of renal dehydropeptidase-I, compared to methicillin in experimental pyelonephritis in rats was investigated. " 02/01/2002 - "Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections." 07/01/1986 - "Twenty-four patients, including 1 with purulent meningitis, 1 with septicemia, 1 with pyothorax, 10 with bronchopneumonia, 7 with pyelonephritis and 4 with infections of cutaneous soft tissue were treated with MK-0787/MK-0791 at dose levels of over 100 mg/100 mg/kg/day with purulent meningitis and septicemia and 28.8 mg/28.8 mg-72.8 mg/72.8 mg/kg/day with other infections. "
3.	Bacterial Infections (Bacterial Infection) 07/01/1986 - "From the present study, MK-0787/MK-0791 appears a safe and effective antibiotic when used in children with a variety of bacterial infections." 07/01/1986 - "The MK-0787/MK-0791 was administered to 13 children with bacterial infections. " 07/01/1986 - "Thirty cases of bacterial infections were treated with MK-0787/MK-0791 at a daily dose of 40 to 222 mg/kg for 2.25 to 13 days. " 06/01/1986 - "Four patients with bacterial infections were treated with MK-0787/MK-0791. " 10/01/1987 - "In a randomized prospective study, 66 patients with serious bacterial infections--mainly lower respiratory tract infections--were treated with either imipenem plus cilastatin (32 patients) or ciprofloxacin (34 patients); 30 patients in each group were evaluable for efficacy. "
4.	Acute Kidney Injury (Acute Renal Failure) 08/01/2010 - "Therefore, cilastatin administration might represent a novel strategy in the prevention of cisplatin-induced acute renal injury." 01/01/1992 - "In patients with acute renal failure, who were treated with continuous arteriovenous hemofiltration (CAVH) or continuous arteriovenous hemodiafiltration (CAVHD), we measured clearance rates of imipenem and cilastatin (Tiënam-500). " 10/01/2005 - "Total body clearance of imipenem during CRRT in patients suffering from acute renal failure was found to range between 89 and 149 ml/min. Total body clearance of cilastatin ranged between 9 and 32 ml/min. Total body clearance of both imipenem and cilastatin was reduced in patients with chronic renal failure. "
5.	Chronic Kidney Failure (Chronic Renal Failure) 08/01/1984 - "The mean plasma half-life of cilastatin varied from 54 min in normals to 798 min in patients with end-stage renal failure. " 08/01/1991 - "Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure." 10/01/2005 - "Total body clearance of imipenem during CRRT in patients suffering from acute renal failure was found to range between 89 and 149 ml/min. Total body clearance of cilastatin ranged between 9 and 32 ml/min. Total body clearance of both imipenem and cilastatin was reduced in patients with chronic renal failure. "

Related Drugs and Biologics

1.	Imipenem
2.	imipenem drug combination cilastatin (Primaxin)
3.	dipeptidase 1
4.	Piperacillin
5.	Sodium
6.	tigecycline (Tygacil)
7.	Clindamycin (Cleocin)
8.	Vancomycin
9.	thienamycin
10.	Aztreonam

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Drug Therapy (Chemotherapy)
3.	Intensive Care (Surgical Intensive Care)
4.	Hysterectomy
5.	Renal Dialysis (Hemodialysis)